Phase II Open Label Study for the Use of Insulin-Sensitizer for Treatment of Cognitive Decline
Status:
Not yet recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study seeks to measure changes in cognition through verbal and visual test procedures
and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters
that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques
in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).